-
公开(公告)号：US20250161411A1
公开(公告)日：2025-05-22
申请号：US18724546
申请日：2022-12-21
Applicant: Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
Inventor： Ingo Mellinghoff , Travis J. Hollmann , Nicholas Socci , Maryam Pourmaleki
IPC: A61K38/20 , A61P35/04 , C12Q1/6886 , G01N33/68
Abstract: The present disclosure provides methods for predicting responsiveness to IL-2 therapy in patients diagnosed with or suffering from melanoma. These methods are based on screening for expression of membranous MHC class I in tumor cells of untreated lesions.
-
公开(公告)号：US20250065334A1
公开(公告)日：2025-02-27
申请号：US18725042
申请日：2022-12-28
Applicant: Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
Inventor： Noah Fichter
Abstract: The approach disclosed herein can provide a closed-loop physical supply chain using a precision vessel. An example vessel includes an outer shell and an inner chamber that fits therein. The inner chamber includes a first compartment to removably house a product, and a second compartment with environmental control mechanisms. An enclosed layer, which may be secured to or integrated with the inner chamber, includes a controller and a communication interface to communicate with devices external to the precision vessel. Multiple sensors that monitor the first compartment send signals to the controller of the enclosed layer. A locking mechanism, when engaged, secures the outer shell to the inner chamber, and when disengaged, unlocks the outer shell from the inner chamber to thereby provide access to the first compartment and the product therein. The vessel can track its conditions and locations, and requires verification prior to disengaging the locking mechanism.
-
公开(公告)号：US20240418704A1
公开(公告)日：2024-12-19
申请号：US18706831
申请日：2022-11-03
Applicant: Memorial Sloan-Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
Inventor： Ross Levine , Robert Lyle Bowman , Michael Robert Waarts
IPC: G01N33/50 , C12N5/0789 , C12N9/22 , C12N15/10 , C12N15/11
Abstract: The present disclosure provides, in some embodiments, methods for culturing and expanding hematopoietic stem cells (HSPCs) comprising a genomic modification associated with clonal hematopoiesis (CH). These cultured and expanded HSPCs are used, in some embodiments, to identify genes that promote CH, to identify inhibitors of CH, and to inhibit CH.
-
公开(公告)号：US20240293481A1
公开(公告)日：2024-09-05
申请号：US18656397
申请日：2024-05-06
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventor： Melody Smith , Marcel Van Den Brink , Anqi Dai , Sean Devlin , Marco Ruella , Andrea Facciabene
IPC: A61K35/742 , A61K35/17 , A61K35/745 , A61K35/747 , A61K39/00 , A61K45/06 , C12Q1/06 , C12Q1/689
CPC classification number: A61K35/742 , A61K35/17 , A61K35/745 , A61K35/747 , A61K39/4611 , A61K39/4631 , A61K39/464412 , A61K39/464417 , A61K45/06 , C12Q1/06 , C12Q1/689 , C12Q2600/106
Abstract: The present disclosure relates to compositions and methods for predicting cancer survival or toxicity in a subject receiving a chimeric antigen receptor (CAR) T cell therapy. The present disclosure further discloses compositions, e.g., pharmaceutical compositions, and methods for treating said subject.
-
公开(公告)号：US20240279601A1
公开(公告)日：2024-08-22
申请号：US18542134
申请日：2023-12-15
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
Inventor： Lorenz STUDER , Yujie Fan
IPC: C12N5/0793 , A61K35/30
CPC classification number: C12N5/0619 , A61K35/30 , C12N2501/115 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/19 , C12N2501/415 , C12N2506/45
Abstract: The present disclosure relates to methods for generating sacral neural crest lineage cells and enteric neurons. Also provided are sacral neural crest lineage cells and enteric neurons generated by the presently disclosed methods and compositions comprising such cells. The present disclosure further provides uses of the sacral neural crest lineage cells and enteric neurons for preventing, modeling, and/or treating of enteric nervous system disorders.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240254564A1
公开(公告)日：2024-08-01
申请号：US18565767
申请日：2022-06-01
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC: C12Q1/6886 , A61K45/06
CPC classification number: C12Q1/6886 , A61K45/06 , C12Q2600/106 , C12Q2600/156
Abstract: The present disclosure relates to methods for detecting chemoresistant SCLC tumors in a patient and/or methods for determining whether a patient diagnosed with small cell lung cancer (SCLC) will benefit from treatment with chemotherapy. These methods are based on screening a SCLC patient for elevated XP01 expression. The present technology also provides methods for sensitizing SCLC patients to chemotherapy using an inhibitor of XP01.
-
公开(公告)号：US20240197879A1
公开(公告)日：2024-06-20
申请号：US18591191
申请日：2024-02-29
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Inventor： Anthony Daniyan , Renier J. BRENTJENS , Ivo C. LORENZ , Abdul KHAN
IPC: A61K39/00 , A61P35/02 , C07K14/705 , C07K14/725 , C07K14/73 , C07K16/28 , C12N5/0783
CPC classification number: A61K39/464411 , A61K39/4611 , A61K39/4631 , A61P35/02 , C07K14/70503 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C07K14/70521 , C07K14/70532 , C07K14/70578 , C07K16/2803 , C12N5/0636 , C07K2317/622 , C07K2319/02 , C07K2319/03
Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD33 and cells comprising such CD33-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD33-targeted antigen-recognizing receptors for treatment.
-
公开(公告)号：US20240131070A1
公开(公告)日：2024-04-25
申请号：US18535469
申请日：2023-12-11
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Inventor： Scott W. Lowe , Michel Sadelain , Corina Amor Vegas , Paul Balderes , Ivo C. Lorenz , Zeda Zhang
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464429 , C07K16/2896 , A61K2239/21 , A61K2239/22 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622
Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
-
公开(公告)号：US20230381315A1
公开(公告)日：2023-11-30
申请号：US18306890
申请日：2023-04-25
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
Inventor： Michel Sadelain , Jorge Mansilla-Soto , Sacha P. Haubner
CPC classification number: A61K39/4631 , A61K39/4621 , A61P37/02 , A61K39/464429
Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule); and a gene disruption of a CD70 locus. The gene disruption of the CD70 locus can improve the activity and/or efficiency of the cells.
-
公开(公告)号：US20250144099A1
公开(公告)日：2025-05-08
申请号：US18690228
申请日：2022-09-08
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , DANA-FARBER CANCER INSTITUTE , STEVENS INSTITUTE OF TECHNOLOGY , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Inventor： Sarat Chandarlapaty , Qing Li , Nathanael Gray , Baishan Jiang , Abhishek Sharma , Aiswarya Mini
IPC: A61K31/519 , A61P35/00 , C07D471/04
Abstract: The present disclosure relates to compounds according to Formula (I), Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, compositions including such compounds, and methods useful for treating, preventing, and/or ameliorating a CDK4 and/or CDK6-mediated disorder, disease, or condition (e.g., cancer such as breast cancer) in a subject.
-
-
-
-
-
-
-
-
-
Search Results
66
records
(took 0.045 seconds)
